Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder


A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder




The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children aged 2-6 years as measured by the change from baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores compared to placebo at 6 months.

Study Status: Active, not recruiting


Condition Intervention Phase
Autistic Disorder Drug: Buspirone
Drug: Buspirone
Drug: Placebo
Phase 2/Phase 3

Verified by Chugani, Diane C. October, 2013

Sponsored by: Chugani, Diane C.
Information provided by: Chugani, Diane C. identifier: NCT00873509

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio 44195
United States

Diane C Chugani, PhD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site